

Article

Supplementary Material: The Role of the Immune Metabolic Prognostic Index in Patients with Non-Small Cell Lung Cancer (NSCLC) in Radiological Progression during Treatment with Nivolumab

Matteo Bauckneht ^{1,*}, Carlo Genova ^{2,3}, Giovanni Rossi ², Erika Rijavec ⁴, Maria Giovanna Dal Bello ², Giulia Ferrarazzo ¹, Marco Tagliamento ², Maria Isabella Donegani ^{1,5}, Federica Biello ⁶, Silvia Chiola ^{1,5}, Lodovica Zullo ⁷, Stefano Raffa ^{1,5}, Francesco Lanfranchi ^{1,5}, Giuseppe Cittadini ⁸, Cecilia Marini ^{5,9}, Egesta Lopci ¹⁰, Gianmario Sambuceti ^{1,5}, Francesco Grossi ⁴ and Silvia Morbelli ^{1,5}




Figure S1. IMPI and IMPIR calculation.